CorMedix Inc. (CRMD)

Market Capitalisation $180 Mln
Price to Earnings Ratio --
12 Month Earnings $-25 Mln

CorMedix Inc. (CRMD) Share Price

NASDAQ

Prev Close
$3.54
Day's Open
$3.55
Today's High
$3.70
Today's Low
$3.48
Today's Volume
488,412
52 Week range
$2.57 - 6.09

CorMedix Inc. (CRMD) Stock Performance

Trailing
Annual

	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
CorMedix (CRMD)	-14.45	3.44	-8.61	-17.58	-24.83	-11.77	0.31
S&P BSE Sensex^*	14.26	7.02	5.52	11.00	15.53	14.51	12.72
S&P Small-Cap 600^#	-5.82	-5.34	-13.73	-6.30	5.30	2.98	5.53

As on 06-Dec-2023 | *As on 07-Dec-2023 | #As on 26-Oct-2023

	2022	2021	2020	2019	2018	2017	2016
CorMedix (CRMD)	-7.25	-38.76	2.06	12.87	155.65	-67.19	-24.63
S&P Small-Cap 600	-17.42	25.27	9.57	20.86	-9.70	11.73	24.74
S&P BSE Sensex	4.44	21.99	15.75	14.38	5.87	27.91	1.95

Valuation

	Stock	Peer Median
Please wait...

Growth & Efficiency

	Stock	Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

More Details about Key Ratios

CorMedix Inc. (CRMD) Peer Comparison

See More Peer Comparisons

Median P/E duration:

Median P/B duration:

Financials

See More Financial Details

Shareholding Pattern

See More Details of Holdings

Other details of CorMedix Inc. (CRMD)

Exec. VP & CFO

Dr. Matthew T. David M.D.

EVP, Gen. Counsel, Head of Regulatory, Compliance, Legal & Technical Operations and Sec.

Dr. Phoebe Mounts Esq., Ph.D.

Headquarters

Berkeley Heights, NJ

Website

https://www.cormedix.com

More Details

FAQs for CorMedix Inc. (CRMD)

What is the total asset value of CorMedix Inc. (CRMD)?

The total asset value of CorMedix Inc. (CRMD) stood at $ 64 Mln as on 31-Mar-23

What is the current share price of CorMedix Inc. (CRMD)?

The share price of CorMedix Inc. (CRMD) is $3.61 (NASDAQ) as of 06-Dec-2023 16:13 EST. CorMedix Inc. (CRMD) has given a return of -24.83% in the last 3 years.

What is the market cap of CorMedix Inc. (CRMD)?

CorMedix Inc. (CRMD) has a market capitalisation of $ 180 Mln as on 30-Jun-2023. As per Value Research classification, it is a Small Cap company.

What is the current PB ratio of CorMedix Inc. (CRMD)?

The P/B ratio of CorMedix Inc. (CRMD) is 2.77 times as on 30-Jun-2023, a 0.09% premium to its peers’ median range of 2.54 times.

What is the current P/E ratio of CorMedix Inc. (CRMD)?

Since, TTM earnings of CorMedix Inc. (CRMD) is negative, P/E ratio is not available.

How can you buy shares of CorMedix Inc. (CRMD)?

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the CorMedix Inc. (CRMD) and enter the required number of quantities and click on buy to purchase the shares of CorMedix Inc. (CRMD).

What is the main business of CorMedix Inc. (CRMD)?

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Who are the promoters/managers of CorMedix Inc. (CRMD)?

The CEO & director of Dr. Matthew T. David M.D.. is CorMedix Inc. (CRMD), and CFO & Sr. VP is Dr. Phoebe Mounts Esq., Ph.D..

What is the total promoter pledging in CorMedix Inc. (CRMD)?

The promoters of CorMedix Inc. (CRMD) have pledged 0% of the total equity as on Mar-23.

Who are the competitors of CorMedix Inc. (CRMD)?

Some of the close peers are:

Company	Market Cap($ Mln)
Y-mAbs Therapeutics (YMAB)	30
Selecta Biosciences (SELB)	17
G1 Therapeutics (GTHX)	13
Hookipa Pharma Inc (HOOK)	7

What are the key ratios of CorMedix Inc. (CRMD)?

CorMedix Inc. (CRMD)	Ratios
Return on equity(%)	--
Return on capital employed(%)	--
Debt-to-equity ratio	0
Dividend yield(%)	0

Is the CorMedix Inc. (CRMD) profitable?

No, TTM profit after tax of CorMedix Inc. (CRMD) was $-25 Mln.

Stock Screeners

Select stocks based on pre-defined filters or customised as per your needs.

Market Monitor

Returns of all major Indian and Global equity indices across time periods.

Who Owns What?

Search a company by name to view which funds hold its shares.

My Investments

Elevate your portfolio with detailed analytics, powerful tools and handpicked recommendations. See how all your investments are performing.

My Watchlist

Keep an eye on the investments you wish to invest in

SIP Calculator

Calculate how much you can accumulate with your monthly savings.

See All Tools

Edit

Key Facts

Market cap $179.92 Mln
Revenue (TTM) $0.06 Mln
Earnings (TTM) $-25.03 Mln
Cash $55.83 Mln
Total Debt $0.77 Mln
Insider's Holding 1.08%
Liquidity High
52 Week range $2.57 - 6.09
Shares outstanding 45,377,800
10 Years Aggregate:

CFO: $-179.55 Mln

EBITDA: $-238.16 Mln

Net Profit: $-228.63 Mln

About The Company

IPO Date 25-Mar-2010
Exec. VP & CFO Dr. Matthew T. David M.D.
EVP, Gen. Counsel, Head of Regulatory, Compliance, Legal & Technical Operations and Sec. Dr. Phoebe Mounts Esq., Ph.D.
Listing NASDAQ: CRMD
Country United States
Headquarters Berkeley Heights, NJ
Website https://www.cormedix.com

Business
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate... is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. Read more

Demystifying Stocks.

At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

What can Value Research do for you?

Solidify your fundamentals

Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

Track all your investments

Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

Get guidance from our experts

Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

Get access to exclusive analytics

Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

Explore All Features

Explore it yourself, for free

Unlimited access to advice from India's top experts

The most comprehensive analysis of funds and stocks in India

A holistic portfolio manager to help track all your investments easily

And much more, like guides, tools, webinars, videos and eBooks.

Recently Viewed